Sarepta Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Sarepta Therapeutics
SRPT Stock  USD 137.94  7.44  5.70%   
Sarepta Therapeutics financial statements provide useful quarterly and yearly information to potential Sarepta Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sarepta Therapeutics financial statements helps investors assess Sarepta Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sarepta Therapeutics' valuation are summarized below:
Gross Profit
-78.1 M
Profit Margin
0.0743
Market Capitalization
13.2 B
Enterprise Value Revenue
8.1539
Revenue
1.6 B
There are currently one hundred twenty fundamental trend indicators for Sarepta Therapeutics that can be evaluated and compared over time across competition. All traders should double-check Sarepta Therapeutics' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 10.7 B in 2024. Enterprise Value is likely to gain to about 11.3 B in 2024

Sarepta Therapeutics Total Revenue

1.31 Billion

Check Sarepta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sarepta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 61.8 M, Interest Expense of 23.1 M or Selling General Administrative of 475.9 M, as well as many indicators such as Price To Sales Ratio of 6.81, Dividend Yield of 0.0 or PTB Ratio of 6.7. Sarepta financial statements analysis is a perfect complement when working with Sarepta Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Sarepta Therapeutics Correlation against competitors.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Sarepta Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.4 B3.3 B1.5 B
Slightly volatile
Other Current Liabilities297.6 M283.4 M97.7 M
Slightly volatile
Total Current Liabilities686.3 M653.7 M244.4 M
Slightly volatile
Total Stockholder Equity902.3 M859.3 M510.3 M
Slightly volatile
Property Plant And Equipment Net375 M357.1 M129.4 M
Slightly volatile
Accounts Payable173.2 M164.9 M55.3 M
Slightly volatile
Cash298.4 M428.4 M525.3 M
Slightly volatile
Non Current Assets Total719.5 M685.2 M257.2 M
Slightly volatile
Non Currrent Assets Other306.6 M292 M79.8 M
Slightly volatile
Cash And Short Term Investments1.8 B1.7 B937.6 M
Slightly volatile
Common Stock Total Equity7.7 K8.1 K213.1 K
Slightly volatile
Common Stock Shares Outstanding97 M92.4 M56.4 M
Slightly volatile
Liabilities And Stockholders Equity3.4 B3.3 B1.5 B
Slightly volatile
Other Stockholder Equity5.6 B5.3 B2.4 B
Slightly volatile
Total Liabilities2.5 B2.4 B974.5 M
Slightly volatile
Property Plant And Equipment Gross575.5 M548.1 M172.9 M
Slightly volatile
Total Current Assets2.7 B2.6 B1.2 B
Slightly volatile
Intangible Assets31.1 M29.6 M11.4 M
Slightly volatile
Common Stock7.7 K8.1 K213.1 K
Slightly volatile
Non Current Liabilities Total1.8 B1.8 B730.4 M
Slightly volatile
Other Current Assets147.5 M140.5 M36 M
Slightly volatile
Other Assets0.951.074.7 M
Slightly volatile
Property Plant Equipment295.8 M281.7 M107.4 M
Slightly volatile
Net Receivables461.7 M439.7 M111.3 M
Slightly volatile
Short and Long Term Debt Total1.5 B1.4 B586.9 M
Slightly volatile
Other Liabilities630.2 M600.2 M211.6 M
Slightly volatile
Long Term Debt1.2 B1.1 B501 M
Slightly volatile
Short Term Debt148.2 M141.2 M62.6 M
Slightly volatile
Net Tangible Assets530.3 M434 M451.8 M
Slightly volatile
Long Term Debt Total1.3 B1.3 B489.5 M
Slightly volatile
Capital Surpluse5 B4.8 B2.3 B
Slightly volatile
Non Current Liabilities Other39 M41.1 M115.1 M
Slightly volatile
Short and Long Term Debt127.4 M121.3 M54.3 M
Slightly volatile
Net Invested Capital1.9 B2.1 B1.5 B
Slightly volatile
Long Term Investments6.2 M6.5 M28.8 M
Very volatile
Net Working Capital1.8 B1.9 B1.4 B
Slightly volatile
Capital Stock9.2 K10.3 K7.8 K
Slightly volatile
Capital Lease Obligations84.9 M158.8 M60 M
Slightly volatile

Sarepta Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization61.8 M58.9 M22.6 M
Slightly volatile
Selling General Administrative475.9 M453.3 M190.9 M
Slightly volatile
Total Revenue1.3 B1.2 B378.4 M
Slightly volatile
Other Operating Expenses1.6 B1.5 B637.5 M
Slightly volatile
Research Development921.3 M877.4 M394.8 M
Slightly volatile
Total Operating Expenses1.4 B1.4 B590.4 M
Slightly volatile
Interest Income71 M67.7 M11.7 M
Slightly volatile
Non Recurring209.2 M199.2 M100.1 M
Slightly volatile
Selling And Marketing Expenses30 M28.6 M7.9 M
Slightly volatile
Reconciled Depreciation31.6 M43.6 M19.3 M
Slightly volatile

Sarepta Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation46.6 M44.4 M17.9 M
Slightly volatile
Capital Expenditures79.9 M76.1 M33.5 M
Slightly volatile
Total Cash From Financing Activities186 M125 M322.4 M
Slightly volatile
Begin Period Cash Flow1 B985.8 M551.2 M
Slightly volatile
Stock Based Compensation191.6 M182.5 M72.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.817.1662157
Slightly volatile
PTB Ratio6.710.36849.5094
Pretty Stable
Days Sales Outstanding123129174
Very volatile
Book Value Per Share5.089.30047.5558
Slightly volatile
Average Payables3 M3.4 M3.7 M
Slightly volatile
Stock Based Compensation To Revenue0.140.14682.3877
Pretty Stable
Capex To Depreciation2.431.71422.2874
Very volatile
PB Ratio6.710.36849.5094
Pretty Stable
EV To Sales7.557.945148
Slightly volatile
Sales General And Administrative To Revenue0.350.36465.936
Pretty Stable
Research And Ddevelopement To Revenue0.670.705713.9543
Pretty Stable
Capex To Revenue0.05820.06120.7862
Slightly volatile
Cash Per Share19.0518.141613.1095
Slightly volatile
Intangibles To Total Assets0.00860.00910.028
Slightly volatile
Current Ratio3.753.9467.6051
Slightly volatile
Tangible Book Value Per Share4.898.97987.3614
Slightly volatile
Receivables Turnover5.342.82774.6368
Slightly volatile
Graham Number18.5634.840426.6436
Slightly volatile
Shareholders Equity Per Share5.099.30047.562
Slightly volatile
Debt To Equity1.531.46140.7755
Slightly volatile
Capex Per Share0.860.82370.4777
Slightly volatile
Average Receivables4.1 M4.1 M3.6 M
Slightly volatile
Revenue Per Share14.1313.45634.7199
Slightly volatile
Interest Debt Per Share14.5213.82996.6588
Slightly volatile
Debt To Assets0.40.38470.2112
Slightly volatile
Price Book Value Ratio6.710.36849.5094
Pretty Stable
Ebt Per Ebit2.041.94191.28
Very volatile
Company Equity Multiplier3.993.79892.5517
Slightly volatile
Long Term Debt To Capitalization0.60.56860.2948
Slightly volatile
Total Debt To Capitalization0.620.59370.3034
Slightly volatile
Debt Equity Ratio1.531.46140.7755
Slightly volatile
Quick Ratio3.283.45217.1976
Slightly volatile
Net Income Per E B T1.321.03051.0479
Pretty Stable
Cash Ratio0.620.65542.7934
Pretty Stable
Days Of Sales Outstanding123129174
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.21.17431.0534
Very volatile
Price To Book Ratio6.710.36849.5094
Pretty Stable
Fixed Asset Turnover1.893.48173.1007
Pretty Stable
Debt Ratio0.40.38470.2112
Slightly volatile
Price Sales Ratio6.817.1662157
Slightly volatile
Asset Turnover0.40.38090.2122
Pretty Stable
Price Fair Value6.710.36849.5094
Pretty Stable

Sarepta Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap10.7 B10.2 B6.3 B
Slightly volatile
Enterprise Value11.3 B10.8 B6.6 B
Slightly volatile

Sarepta Fundamental Market Drivers

Forward Price Earnings11.1607
Cash And Short Term Investments1.7 B

Sarepta Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Sarepta Therapeutics Financial Statements

Sarepta Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Sarepta Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Sarepta Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sarepta Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue50.4 M52.9 M
Total Revenue1.2 B1.3 B
Cost Of Revenue150.3 M157.9 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue 0.36  0.35 
Research And Ddevelopement To Revenue 0.71  0.67 
Capex To Revenue 0.06  0.06 
Revenue Per Share 13.46  14.13 
Ebit Per Revenue(0.22)(0.23)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY